Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Commercial Officer | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,001 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 1,541 · Balance 11,001 F1: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2026 Filed Jul 7, 2026 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,541 | $519.00 | $799,779.00 |
DisclosureSEC source: 0000875320-26-000243 · wk-form4_1783454880.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,001 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,633 | $498.42 | $1,312,339.86 |
DisclosureSEC source: 0000875320-26-000138 · wk-form4_1773432707.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,489 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,437 | $475.30 | $1,158,306.10 |
DisclosureSEC source: 0000875320-26-000136 · wk-form4_1772831152.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,122 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,410 | $489.00 | $1,178,490.00 |
DisclosureSEC source: 0000875320-26-000116 · wk-form4_1772149699.xml · nonDerivative · entry 3 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,559 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $486.35 | $1,215,875.00 |
DisclosureSEC source: 0000875320-26-000116 · wk-form4_1772149699.xml · nonDerivative · entry 2 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,969 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 873 | $485.11 | $423,501.03 |
DisclosureSEC source: 0000875320-26-000116 · wk-form4_1772149699.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,469 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,148 | $483.75 | $555,345.00 |
DisclosureSEC source: 0000875320-26-000094 · wk-form4_1771536070.xml · nonDerivative · entry 2 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,342 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,962 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000094 · wk-form4_1771536070.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,490 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,283 | $487.76 | $1,113,556.08 |
DisclosureSEC source: 0000875320-26-000072 · wk-form4_1771450668.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,528 Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,127 | $468.41 | $527,898.07 |
DisclosureSEC source: 0000875320-26-000048 · wk-form4_1770933853.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,811 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000022 · wk-form4_1769463011.xml · nonDerivative · entry 2 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,938 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000022 · wk-form4_1769463011.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,858 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.